However, the different signaling dynamics between these pathways in myeloma cells could also suggest that there are different receptor complexes that relay the signal to each of the SMAD branches, i.e., activins do not activate ALK2 and ALK4/ALK7 via a common heteromeric receptor complex. This evidence concerns the gene ACVR1C and plasma cell myeloma.